Clinical Trial Update: Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 [Phase 1]

View source ↗

Summary

Phase 1 intravenous study of TKM-100802 for Ebola virus disease reported safety, tolerability, and pharmacokinetics; the trial is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• TKM-100802

Snippet

Sponsor: Arbutus Biopharma Corporation | Conditions: Ebola Virus Infection | Phase 1 | Status: TERMINATED